Linagliptin-associated blistering and ulceration
| Autor: | Naima Shahzad, Cristina Psomadakis, Jonathan Katz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Side effect Secondary infection Administration Oral Linagliptin Type 2 diabetes Diagnosis Differential 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Blister Diabetes mellitus medicine Humans Hypoglycemic Agents 030212 general & internal medicine Dipeptidyl peptidase-4 Dipeptidyl-Peptidase IV Inhibitors integumentary system Skin Diseases Vesiculobullous business.industry Blisters General Medicine Middle Aged medicine.disease Dermatology Surgery Diabetes Mellitus Type 2 Hospital admission medicine.symptom business medicine.drug Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect |
| Popis: | We present the case of 60-year-old man with type 2 diabetes who developed blistering after two sequential exposures to linagliptin. Linagliptin is one of the dipeptidyl peptidase 4 (DPP-4) inhibitors, a group of oral hypoglycaemic agents used commonly for the treatment of type 2 diabetes. On the first exposure to linagliptin, he developed blisters on the hands which resolved after stopping the drug. After repeat exposure, he developed two large blisters on the left foot, which burst giving rise to secondary infection, requiring hospital admission for treatment. We discuss the latest research linking DPP-4 inhibitors with adverse skin reactions and the effect of ulcers on the morbidity and mortality of patients with diabetes. This case report highlights skin reactions as an important, rare and lesser known side effect of DPP-4 inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|